Herceptin resistance in HER2-moderately expressed breast cancer

<p>HER2 overexpression occurs in approximately 15-20% of all breast cancers and is associated with poor prognosis. The development of Herceptin, a monoclonal antibody against HER2, has been significant in prolonging survival of these patients. Herceptin is less efficient in patients who do not...

Descrizione completa

Dettagli Bibliografici
Autori principali: Kerry, J, Jonathan Kerry
Altri autori: Kong, A
Natura: Tesi
Lingua:English
Pubblicazione: 2012
Soggetti: